Madrigal Pharmaceuticals

MDGLApproved

Madrigal Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing novel therapeutics for MASH, formerly known as NASH. The company has successfully brought the first FDA-approved treatment for MASH to market in the U.S. and EU, marking a historic milestone in liver disease treatment. Madrigal's innovative THR-β agonist platform addresses the underlying causes of liver fibrosis and metabolic dysfunction, with multiple Phase 3 trials ongoing to expand treatment options for MASH patients.

Market Cap

$10.1B

Employees

hundreds

Focus

Small Molecules

MDGL · Stock Price

USD 441.16+346.48 (+365.95%)

Historical price data

AI Company Overview

Technology Platform

Thyroid hormone receptor-beta (THR-β) agonist platform targeting liver metabolism, inflammation, and fibrosis progression in MASH patients.

Pipeline Snapshot

17 drugs in pipeline, 4 in Phase 3

Drug	Indication	Stage
MGL-3196 + Placebo	NASH - Nonalcoholic Steatohepatitis	Phase 3
Resmetirom + Placebo	NASH	Phase 3
Resmetirom	Non-Alcoholic Fatty Liver Disease	Phase 3
Placebo + Resmetirom	Non-Alcoholic Fatty Liver Disease	Phase 3
Resmetirom + Placebo	MASH - Metabolic Dysfunction-Associated Steatohepatitis	Phase 2

Funding History

Total raised: $166M

IPO$86MUndisclosedSep 22, 2016

Series B$60MUndisclosedJun 15, 2015

Series A$20MUndisclosedJun 15, 2011

FDA Approved Drugs

REZDIFFRANDAMar 14, 2024

Opportunities

Madrigal has significant growth opportunities through expanding their approved MASH treatment to broader patient populations via ongoing Phase 3 trials, developing combination therapies, and leveraging their first-mover advantage in a large underserved market.

The company can also expand globally and develop next-generation liver-directed therapies.

Risk Factors

Key risks include market adoption challenges for the first MASH treatment, emerging competition from other companies now entering the validated MASH market, regulatory hurdles for pipeline expansion, and dependence on a single commercial product.

Reimbursement and access challenges across different healthcare systems also pose risks to commercial success.

Competitive Landscape

Madrigal has established a dominant first-mover position in MASH therapeutics, having transformed what was previously considered a 'graveyard' for drug development into a validated therapeutic area. While their breakthrough has opened the field to new entrants, Madrigal maintains significant competitive advantages through their established commercial presence, deep MASH expertise, and multiple ongoing Phase 3 studies expanding their addressable market.

Publications

Patents

Pipeline

FDA Approvals